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Abstract: OBJECTIVE: To assess the change in health-related quality of life (HRQoL) in patients
undergoing mastoid cavity obliteration. METHODS: Patients who had undergone canal wall-down mas-
toidectomy for chronic otitis media with creation of a persistent mastoid cavity and underwent revision
tympanomastoid surgery including mastoid cavity obliteration using autologous material were included.
Audiological measurements including air conduction (AC) and bone conduction (BC) pure-tone averages
(PTA) and the air-bone gap (ABG) were assessed. Health-related Quality of Life (HRQoL) was assessed
by the Zurich Chronic Middle Ear Inventory (ZCMEI-21) pre- and postoperatively. RESULTS: A total
of 25 patients (16 females and 9 males; mean age 51.6 years, 14 right and 11 left ears) were included.
Patients were reexamined after a mean follow-up period of 9.2 months (SD = 6.5) after obliteration of
the mastoid cavity. Compared to the preoperative visit, patients showed a significantly reduced AC PTA
at the postoperative visit (mean difference: - 4.1; SD = 10.4, p = 0.045). The mean ZCMEI-21 score
changed from 31.7 (SD = 14.5) preoperatively to 17.4 (SD = 15.1) postoperatively (mean difference: -
14.3; SD = 19.1; p = 0.0002). The mean ZCMEI-21 score changes were neither correlated to the AC
PTA shift (p = 0.60) nor to the ABG shift (p = 0.66). CONCLUSIONS: This is the first study reporting
a highly significant and clinically important improvement in HRQoL after mastoid cavity obliteration in
a prospective setting. The improvement in HRQoL was not correlated to the hearing improvement. As
a clinical implication, we provide evidence for a substantial subjective benefit of the surgical obliteration
of a symptomatic mastoid cavity and, therefore, encourage this surgical procedure.
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Abstract
Objective To assess the change in health-related quality of life (HRQoL) in patients undergoing mastoid cavity obliteration.
Methods Patients who had undergone canal wall-down mastoidectomy for chronic otitis media with creation of a persistent 
mastoid cavity and underwent revision tympanomastoid surgery including mastoid cavity obliteration using autologous 
material were included. Audiological measurements including air conduction (AC) and bone conduction (BC) pure-tone 
averages (PTA) and the air–bone gap (ABG) were assessed. Health-related Quality of Life (HRQoL) was assessed by the 
Zurich Chronic Middle Ear Inventory (ZCMEI-21) pre- and postoperatively.
Results A total of 25 patients (16 females and 9 males; mean age 51.6 years, 14 right and 11 left ears) were included. Patients 
were reexamined after a mean follow-up period of 9.2 months (SD = 6.5) after obliteration of the mastoid cavity. Compared 
to the preoperative visit, patients showed a significantly reduced AC PTA at the postoperative visit (mean difference: − 4.1; 
SD = 10.4, p = 0.045). The mean ZCMEI-21 score changed from 31.7 (SD = 14.5) preoperatively to 17.4 (SD = 15.1) post-
operatively (mean difference: − 14.3; SD = 19.1; p = 0.0002). The mean ZCMEI-21 score changes were neither correlated 
to the AC PTA shift (p = 0.60) nor to the ABG shift (p = 0.66).
Conclusions This is the first study reporting a highly significant and clinically important improvement in HRQoL after mas-
toid cavity obliteration in a prospective setting. The improvement in HRQoL was not correlated to the hearing improvement. 
As a clinical implication, we provide evidence for a substantial subjective benefit of the surgical obliteration of a symptomatic 
mastoid cavity and, therefore, encourage this surgical procedure.
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Introduction
Historically, in extended inflammation processes of the middle 
ear and mastoid, an open mastoid cavity was created without 
reconstruction under the aim of draining the disease into the 
bony outer ear canal [1]. Nowadays, the primary creation of a 
mastoid cavity is performed as part of a canal wall-down mas-
toidectomy in cases of large cholesteatoma or inflammatory 
processes inside the mastoid [2]. Depending on the extent of 
the mastoid cavity and the size of the external auditory canal, 
the self-cleaning process of the mastoid cavity may be dis-
turbed, leading to recurrent infections, secretion, vertigo, hear-
ing impairment, and frequent consultation of an ENT special-
ist [3]. In these cases, the treatment of choice consists of the 
secondary surgical obliteration of the mastoid cavity as first 
described by Mosher in 1911 [4]. Multiple methods and mate-
rials for cavity obliteration, which is commonly performed 
in combination with meatoplasty, have been developed and 
tested [5, 6]. Usually, the use of autologous material is pre-
ferred due to its good biocompatibility. Cartilage, either from 
the concha, tragus or nasal septum, muscle flaps, bone pâté 
or fascia are used. Drawback of autologous material may be 
natural shrinkage and the limited availability of after repeated 
revision surgery [7]. Additionally, several xenografts and 
alloplastic materials have been designed and tested in clinical 
and experimental settings [8–10]. However, the mechanism 
of biomaterial-based regeneration processes has still to be 
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understood and recent work concerning allogeneic materials 
showed an insufficient cavity obliteration and high rates of 
revision surgery [11].
In cases of a persistent mastoid cavity, symptoms such 
as chronic ear discharge, ear pain, and hearing impairment 
may severely impair patient’s health-related quality of life 
(HRQoL). Furthermore, it has been reported that hearing 
impairment is a major risk factor for the development of 
dementia and cognitive dysfunction [12]. It has to be assumed 
that the patient’s subjective benefit from tympanomastoid sur-
gery is not only determined by the postoperative reduction of 
the air–bone gap (ABG) [13]. Therefore, focusing on the audi-
ological outcome alone may only insufficiently assess the sur-
gical results [14]. Moreover, patient-reported outcome meas-
ures are being used increasingly and have gained importance 
to measure therapeutic success [15, 16]. Usually, standardized 
questionnaires investigating everyday life situations, difficul-
ties in communication or social contacts, and co-symptoms 
like tinnitus are used to assess the impairment due to hearing 
handicap [17, 18]. The Glasgow benefit inventory (GBI) is 
used to report the subjective success of otosurgical interven-
tions [19, 20]. However, disadvantages of the GBI include the 
exclusively retrospective application, and therefore, changes 
in HRQoL cannot be reported reliably. In contrast, the Zurich 
Chronic Middle Ear Inventory-21 (ZCMEI-21) was designed 
as a disease-specific instrument assessing disease-specific 
symptoms and their impact on quality of life in chronic otitis 
media (COM) [11, 15, 21–23]. The responsiveness to change 
of the ZCMEI-21 has been recently investigated, thus increas-
ing its clinical utility and facilitating comparisons among dif-
ferent surgical interventions [24].
To our knowledge, HRQoL in patients undergoing mastoid 
cavity obliteration has never been studied in a prospective set-
ting using a disease-specific HRQoL instrument. In the past, 
conflicting results about the change in quality of life have been 
obtained using generic questionnaires (e.g., the GBI) in three 
small retrospective cohort studies [25–27]. Whereas two stud-
ies reported a subjective benefit from surgery [25, 26], another 
study reported a majority of patients experiencing no change 
in quality of life after mastoid obliteration [27]. Therefore, the 
aim of this study was to systematically investigate the change 
in HRQoL in patients undergoing mastoid cavity obliteration 
in a prospective setting using a disease-specific instrument.
Methods
Ethical consideration
The study protocol was approved by the local Ethics Com-
mittee in accordance with the Helsinki declaration (Reg-
istration-number: A2017-0101). Informed consent was 
obtained from all the participants.
Study design and patient selection
In this prospective follow-up study, consecutive adult 
patients receiving mastoid cavity obliteration were 
assessed for inclusion between July 2017 and October 
2019 in a tertiary referral center of a university hospital. 
The main inclusion criterium was a preexisting mastoid 
cavity after mastoidectomy using a canal wall-down tech-
nique without primary reconstruction. Patients undergo-
ing cholesteatoma surgery and cavity obliteration or canal 
reconstruction within the same surgery were excluded. 
Autologous reconstruction material (local pedicled mus-
cle flaps, bone paté, temporal muscle fascia, and cartilage) 
was used to obliterate the open mastoid cavity and/or to 
reconstruct the posterior canal wall. In cases with persis-
tent ABG, ossiculoplasty was performed to improve the 
hearing. Patients completed preoperative and postopera-
tive study visits. Patients included in the study underwent 
pure-tone audiometry and completed the ZCMEI-21 ques-
tionnaire at both visits. No children were included in the 
study.
Audiometric assessment
All audiometric measurements were performed with 
calibrated instruments in a sound-proof room (DIN EN 
ISO 8253) by audiologically trained staff. Measurements 
included standard pure-tone audiometry, performed with 
a clinical audiometer (AT1000, Auritec, Hamburg, Ger-
many) in 5 dB steps. The ABG was calculated as the dif-
ference between the pure-tone average (PTA) of the air 
conduction (AC) PTA measured at 0.5, 1, 2, and 3 kHz 
 (PTA0.5–3 kHz) and the respective bone conduction (BC) 
PTA. According to recommendations in hearing report-
ing standard [28] and to the Committee on Hearing Equi-
librium guidelines [29], the  ABG0.5–3 kHz was chosen for 
evaluating the results of treating conductive hearing loss. 
Therefore, only the  ABG0.5–3 kHz was further analyzed and 
is referred to as ABG. Audiometry was performed pre- and 
postoperatively.
ZCMEI‑21 Questionnaire
The ZCMEI-21 was used to assess HRQoL [15]. The 
ZCMEI-21 as a disease-specific questionnaire for chronic 
middle ear disease has been translated in several languages 
[21, 22, 30] and is used in clinical settings for research 
and clinical practice [11, 15]. The ZCMEI-21 consists of 
four subscales concerning ear signs and symptoms, hear-
ing function, psychosocial impact, and the use of medical 
resources. Answers are presented using a five-point Likert-
scale. Higher scores indicate a poorer quality of life [15] 
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and the minimal clinically important difference (MCID) 
is estimated to 5 [24]. The ZCMEI-21 was designed as a 
disease-specific instrument to assess HRQoL in patients 
suffering from chronic middle ear disease and may also 
be used after surgical interventions. The ZCMEI-21 was 
completed prior surgery and at the follow-up visit after 
surgery.
Statistical analysis
All statistical tests were selected before data collection. 
Statistical analyses were performed using Microsoft Excel 
(version 15.29, Microsoft Corporation, Redmond, WA, 
USA) and Prism (version 8, GraphPad Software, La Jolla, 
CA, USA). The significance level was set to p < 0.05. The 
assumption of normality in AC and ABG distributions was 
tested graphically using quantile–quantile plots and with the 
Kolmogorov–Smirnov test. If not otherwise specified, data 
are presented as mean with standard deviation (SD) or abso-
lute numbers with percentages. A paired sample Student’s t 
test was performed to compare pre- and postoperative means 
in audiometric outcomes and ZCMEI-21 scores. Correla-
tions were calculated using Pearson’s correlation coefficient.
Results
A total of 31 patients receiving secondary tympanomastoid 
surgery using autologous reconstruction material between 
July 2017 and October 2019 were assessed for inclusion. 
Postoperative data were available of 25 patients (16 females 
and 9 males; mean age 51.6 years, 14 right and 11 left ears) 
and were analyzed. The mean time period between the oblit-
eration of the open mastoid cavity and the postoperative 
follow-up visit was 9.2 months (SD = 6.5). At the postopera-
tive visit, the mastoid cavity was sufficiently obliterated and 
observable in 24 cases (96%). One patient (4%) underwent 
revision surgery due to a necrotic muscle flap 1 month after 
obliteration surgery.
Audiological outcomes
Compared to the preoperative visit, patients showed a statis-
tically significant reduction in AC threshold at the postoper-
ative follow-up visit (mean difference: − 4.1 dB; SD = 10.4, 
p = 0.045; Fig. 1a). No significant difference was found 
between the pre- and postoperative BC thresholds (mean dif-
ference: − 1.8 dB; SD = 7.1, p = 0.19; Fig. 1b) and the ABG 
(mean difference: − 2.32; SD = 9.32; p = 0.20; Fig. 1c). Only 
one patient (4%) showed a clinically relevant deterioration of 
hearing (defined as > 10 dB AC) and six patients (24%) had 
an improvement of hearing of more than 10 dB AC.
Medical resources
The number of consultations in the past 6 months of an 
ENT doctor decreased from a mean of 4.0 (SD = 2.3) con-
sultations to 2.0 (SD = 2.6).
Health‑related quality of life
The ZCMEI-21 total score changed from 31.7 (SD = 14.5) 
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Fig. 1  Audiometric outcomes after mastoid cavity obliteration. Pre- and postoperative air conduction (AC) (a) and bone conduction (BC) (b) 
pure-tone average (PTA) as well as the air–bone gap (ABG). The bold line represents the mean; error bars indicate standard deviation
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difference: − 14.3; SD = 19.1; p = 0.0002; Fig. 2). The 
mean change of subscore I (ear signs and symptoms) 
was 0.2 (SD = 9.3; p = 0.93; Fig. 3a). Subscore II (hear-
ing) showed a mean change of − 3.0 (SD = 6.5; p = 0.02; 
Fig.  3b), subscore III (psychosocial impact) of −  6.3 
(SD = 8.9; p = 0.0004; Fig. 3c), and subscore IV (medical 
resources) of − 0.2 (SD = 2.4; p = 0.63; Fig. 3d). No cor-
relation between the change of the ZCMEI-21 total score 
and the AC change as well as between the change of the 
ZCMEI-21 hearing subscore and the change of the AC 
threshold was observed (Fig. 4).
The patients with an improvement of hearing (> 10 dB) 
did not show a higher ZCMEI-21 score shift (mean: 
−  6.6; SD: 19.6) compared to the mean of the entire 
cohort. Patients with a mild-to-moderate hearing handi-
cap of < 50 dB AC (n = 14; 56%) after surgery had a mean 
improvement of 7.2 dB AC (SD = 11.3 dB). The mean 
ZCMEI-21 score change of these patients was −  6.9 
(SD = 16.4).
Discussion
Mastoid cavity obliteration is performed to reduce symp-
toms such as caloric vertigo and otorrhea, and to improve 
patient’s HRQoL including the reduction in frequency of 
ENT specialist consultations [6, 31]. In this study, a sig-
nificant and clinically important improvement in HRQoL 
in patients undergoing mastoid cavity obliteration is 
demonstrated.
To our best knowledge, this is the first study to prospec-
tively report an improvement in disease-specific HRQoL 
in patients undergoing mastoid cavity obliteration. Dorn-
hoffer et al. were the first to draw attention to this topic by 
studying a small patient sample in a retrospective setting 
[25]. An increase of quality of life after mastoid oblitera-
tion and restoration of the middle ear space with cartilage 
reconstruction of the tympanic membrane was reported. 
Quality of life was assessed using the GBI, which is a 
generic questionnaire that measures change in quality of 
life and yields no information on the current quality of life. 
Moreover, this questionnaire is not disease-specific, which 
renders the instrument less sensitive to specific signs and 
symptoms [32]. The GBI was also used in another small 
retrospective cohort study demonstrating improved qual-
ity of life in 10 out of 12 (83%) patients after mastoid 
cavity obliteration with autologous bone [26]. In contrast, 
Joseph et al. recently reported less favorable results in ten 
patients with only four (40%) patients experiencing an 
improvement after mastoid cavity obliteration [27]. As a 
side note, the use of autologous obliteration material is 
recommended in open mastoid cavity and a positive influ-
ence on HRQoL has been reported [33].
Since clinical audiometry is performed in 5 dB steps, 
a mean improvement in the AC of only 4 dB is not con-
sidered clinically relevant. When analyzing the patients 
with higher improvement of hearing (> 10 dB) or smaller 
hearing handicap (< 50 dB) after surgery even smaller 
improvements in the total ZCMEI-21 score were observed 
compared to the complete cohort. Thus, it is assumed that 
although an overall hearing improvement was observed, 
the improvement in HRQoL cannot be attributed to the 
hearing improvement.
In the present study, the pre- and postoperative HRQoL 
using a disease-specific instrument, i.e., the ZCMEI-21 
[15] was prospectively evaluated. The ZCMEI-21 was 
originally designed for prospective investigations and 
has been applied successfully in clinical trials [11, 24, 
34]. In our cohort, a mean preoperative ZCMEI-21 total 
score of around 32 points which indicates an at least mod-
erately impaired HRQoL [15] was found. After surgery, 
the mean ZCMEI-21 total score decreased to around 17 
points. This value corresponds to no or a slight impairment 
in HRQoL [15]. The observed change of the ZCMEI-21 
total score in this study corresponds to a large clinically 
important change [24]. This change was independent from 
the hearing improvement, since no correlation between the 
AC threshold change and the questionnaire change was 
observed. Interestingly, the two subscores that showed the 
highest change were the subscore II (hearing) and sub-
score III (psychosocial impact). Therefore, it is assumed 
that primarily symptoms such as otorrhea and foetor, but 























Fig. 2  Pre- and postoperative ZCMEI-21 total scores. A lower 
ZCMEI-21 total score corresponds to a better HRQoL. The bold line 
represents the mean; error bars indicate standard deviation
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mastoid cavities. Furthermore, the applicability of hearing 
aids may be complicated by a symptomatic mastoid cavity 
and may also maintain a draining cavity. Taken together, 
the results of this study indicate a highly significant and 
clinically important improvement in HRQoL after mastoid 
cavity obliteration and consequently encourage this proce-
dure. Moreover, the results are in line with previous stud-
ies, showing that the use of autologous material is safe and 
effective [6, 33]. It is highly recommended to use recon-
structive measures during primary surgery. Large cavities 
Fig. 3  Changes in the ZCMEI-
21 subscores. Subscores include 
subscore I [ear signs and symp-
toms; (a)], subscore II [hearing; 
(b)] subscore III [psychosocial 
impact; (c)], and subscore IV 
[medical resources; (d)]. A 
lower ZCMEI-21 total score 
corresponds to a better HRQoL. 
The bold line represents the 






























































































Fig. 4  Scatter plot showing 
the association between the 
ZCMEI-21 total score (a) and 
hearing subscore (b) changes 
and the AC PTA change























r = - 0.11, p = 0.60
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during primary should be avoided. In small mastoids with 
little or no aeration, small stable cavities might be achiev-
able if surgical principles are followed. These include a 
smooth cavity with a floor which is even to the outer ear 
canal (no facial ridge) enabling an epithelization of the 
cavity without retention. The meatal entrance must be in 
proportion to the cavity behind.
This study has several limitations. First, a relatively 
small cohort was studied, which may be explained by the 
fact that mastoid cavity creation during primary surgery has 
become less frequent. On the other hand, due to a lack of 
knowledge, patients with discharging cavities may not be 
provided with information about further surgical treatment 
options. Patients with dry cavities with only calorically trig-
gered complaints may be reluctantly referred for revision 
surgery. However, this cohort is larger than all the cohorts in 
which quality of life has been retrospectively assessed after 
mastoid cavity obliteration in the past [25–27]. Second, this 
study may exhibit a selection bias, since only symptomatic 
patients underwent surgery and were included. Asympto-
matic patients usually are not referred to hospital and may 
not profit from cavity obliteration. This bias may lead to 
an overestimation of the treatment efficacy. Yet, the results 
of this study corroborate the notion that—if properly indi-
cated—mastoid cavity obliteration has a substantial impact 
on patient’s HRQoL.
Conclusion
Mastoid cavity obliteration with autologous material leads 
to a highly significant and clinically important improvement 
of HRQoL. This improvement in HRQoL is not related to 
the hearing improvement. It can be concluded that in cases 
of a symptomatic mastoid cavity, surgical obliteration pro-
vides a substantial subjective benefit regarding HRQoL and, 
therefore, patients can be encouraged to undergo this surgi-
cal procedure.
Acknowledgements Open Access funding provided by Projekt DEAL.
Funding No funding was received.
Compliance with ethical standards 
Conflict of interest The authors declare no conflict of interest.
Ethical approval The study protocol was approved by the local Ethics 
Committees in accordance with the Helsinki declaration.
Informed consent Informed consent was obtained from all the par-
ticipants.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Zaufal E (1894) Zur Geschichte und Technik der operativen Frei-
legung der Mittelohrräume. In: Archiv für Ohrenheilkunde, XXX-
VII Bd. p. 33–80.
 2. Wullstein HL (1978) Tympanoplasty: the fundamentals of the 
concept. Clin Otolaryngol Allied Sci 3(4):431–435
 3. Harris AT, Mettias B, Lesser THJ (2016) Pooled analysis of the 
evidence for open cavity, combined approach and reconstruction 
of the mastoid cavity in primary cholesteatoma surgery. J Laryn-
gol Otol 130(3):235–241
 4. Mosher HP (1911) A method of filling the excavated mastoid with 
a flap from the back of the auricle. Laryngoscope 21:1158
 5. Black B (1998) Mastoidectomy elimination: obliterate, recon-
struct, or ablate? Am J Otol 19:551
 6. Roberson JBJ, Mason TP, Stidham KR (2003) Mastoid oblitera-
tion: autogenous cranial bone pAte reconstruction. Otol Neurotol 
24(2):132–140
 7. Klinge B, Alberius P, Isaksson S, Jönsson J (1992) Osseous 
response to implanted natural bone mineral and synthetic hydrox-
ylapatite ceramic in the repair of experimental skull bone defects. 
J Oral Maxillofac Surg 50:241
 8. Yung MW (1996) The use of hydroxyapatite granules in mastoid 
obliteration. Clin Otolaryngol Allied Sci 21:480
 9. Damien CJ, Parsons JR (1991) Bone graft and bone graft sub-
stitutes: a review of current technology and applications. J Appl 
Biomater 2:187
 10. Punke C, Zehlicke T, Boltze C, Pau HW (2008) Experimental 
studies on a new highly porous hydroxyapatite matrix for oblite-
rating open mastoid cavities. Otol Neurotol [Internet]. 29(6):807–
11. https ://www.ncbi.nlm.nih.gov/pubme d/18667 940
 11. Weiss NM, Stecher S, Bächinger D, Schuldt T, Langner S, Zonnur 
S et al (2020) Open mastoid cavity obliteration with a high-poros-
ity hydroxyapatite ceramic leads to high rate of revision surgery 
and insufficient cavity obliteration. Otol Neurotol 41(1):e55–e63. 
https ://doi.org/10.1097/MAO.00000 00000 00241 3
 12. Arlinger S (2003) Negative consequences of uncorrected hearing 
loss: a review. Int J Audiol 42(2):2S17–2S20
 13. Choi SY, Cho Y-SS, Lee NJ, Lee J, Chung W-HH, Hong SH 
(2012) Factors associated with quality of life after ear surgery in 
patients with chronic otitis media. Arch Otolaryngol Head Neck 
Surg 138(9):840–845
 14. Hallberg LRM, Hallberg U, Kramer SE (2008) Self-reported hear-
ing difficulties, communication strategies and psychological gen-
eral well-being (quality of life) in patients with acquired hearing 
impairment. Disabil Rehabil 30(3):203–212
 15. Bächinger D, Röösli C, Ditzen B, Huber AM (2016) Develop-
ment and validation of the Zurich Chronic Middle Ear Inventory 
(ZCMEI-21): an electronic questionnaire for assessing quality of 
European Archives of Oto-Rhino-Laryngology 
1 3
life in patients with chronic otitis media. Eur Arch Oto-Rhino-
Laryngology 273:3073
 16. Lailach S, Schenke T, Baumann I, Walter H, Praetorius M, 
Beleites T et al (2017) Development and validation of the stape-
splasty outcome test 25 (SPOT-25). HNO 65(12):973–980
 17. Newman CW, Weinstein BE (1988) The hearing handicap inven-
tory for the elderly as a measure of hearing aid benefit. Ear Hear 
9(2):81–85
 18. Newman CW, Weinstein BE, Jacobson GP, Hug GA (1990) The 
Hearing handicap inventory for adults: psychometric adequacy 
and audiometric correlates. Ear Hear 11(6):430–433
 19. Hazenberg AJC, Hoppe FF, Dazert S, Minovi A (2013) Meas-
urement of quality of life following stapes surgery. HNO 
61(3):233–239
 20. Weiss NM, Schuldt S, Großmann W, Oberhoffner T, Ginzkey 
C, Schraven SP et al (2019) Stapes surgery leads to significant 
improvement in Quality-of-Life, independently from the surgical 
method. Eur Arch Otorhinolaryngol 276(11):2975–2982. https ://
doi.org/10.1007/s0040 5-019-05577 -4
 21. Chatzimichalis M, Epprecht L, Weder S, Shaul C, Engle Folchert 
KJ, Machala MC et al (2019) English translation and validation of 
the Zurich Chronic Middle Ear Inventory (ZCMEI-21-E) assess-
ing quality of life in chronic otitis media: A prospective interna-
tional multicentre study. Clin Otolaryngol 44:254–262
 22. Ralli M, Quaranta N, Canale A, Röösli C, Milella C, De RV 
et  al (2018) Cross-cultural adaption and validation of the 
Zurich Chronic Middle Ear Inventory translated into Italian 
(ZCMEI-21-It)—a prospective Multicenter study. Otol Neurotol 
40(3):351–358
 23. Reetz T, Lailach S, Garthus-Niegel S, Neudert M, Zahnert T 
(2019) Einfluss von Depressivität auf die krankheitsspezifische 
Lebensqualität bei Patienten mit chronischer Otitis media. In: 
Abstract- und Posterband–90 Jahresversammlung der Deutschen 
Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie eV, 
Bonn–Digitalisierung in der HNO-Heilkunde. 2019.
 24. Bächinger D, Mlynski R, Weiss NM (2020) Determining the mini-
mal clinical important difference (MCID) of the Zurich Chronic 
Middle Ear Inventory 21 (ZCMEI-21) in patients treated for 
chronic middle ear disease. Eur Arch Otorhinolaryngol. https ://
doi.org/10.1007/s0040 5-020-05819 -w
 25. Dornhoffer JL, Smith J, Richter G, Boeckmann J (2008) Impact on 
quality of life after mastoid obliteration. Laryngoscope 118:1427
 26. Kurien G, Greeff K, Gomaa N, Ho A (2013) Mastoidectomy and 
mastoid obliteration with autologous bone graft: a quality of life 
study. J Otolaryngol Head Neck Surg 42:49
 27. Joseph J, Miles A, Ifeacho S, Patel N, Shaida A, Gatland D et al 
(2015) Comparison of quality of life outcomes following different 
mastoid surgery techniques. J Laryngol Otol 129:835
 28. Lailach S, Zahnert T, Neudert M (2017) Data and reporting qual-
ity in tympanoplasty and ossiculoplasty studies. Otolaryngol Head 
Neck Surg (United States) 157:281
 29. Committee on Hearing and Equilibrium (1995) Guidelines for 
the evaluation of results of treatment of conductive hearing loss. 
Otolaryngol Neck Surg [Internet] 113(3):186–7. https ://journ als.
sagep ub.com/doi/10.1016/S0194 -5998%2895%29701 03-6
 30. Bächinger D, Takagi D, Yamada H, Teraoka M, Okada M, Hyodo 
J et al (2018) Japanese translation, cross-cultural adaption and 
multicentre validation of the Zurich Chronic Middle Ear Inventory 
(ZCMEI-21-Jap). Auris Nasus Larynx 46(1):18–23
 31. Beutner D, Stumpf R, Zahnert T, Huttenbrink KB et al (2007) 
Long-term results following mastoid obliteration in canal 
wall down tympanomastoidectomy. Laryngorhinootologie 
86(12):861–866
 32. Guyatt GH, Bombardier C, Tugwell PX (1986) Measuring dis-
ease-specific quality of life in clinical trials. Can Med Assoc J 
134(8):889–895
 33. Alves RD, Cabral Junior F, de Fonseca AC, Bento RF (2016) Mas-
toid obliteration with autologous bone in mastoidectomy canal 
wall down surgery: a literature overview. Int Arch Otorhinolaryn-
gol 20(1):76–83
 34. Weiss NM, Bächinger D, Rrahmani A, Botzen J, Huber A, Mlyn-
ski R et al (2020) Mapping the ChOLE classification to hearing 
outcomes and disease-specific health-related quality of life. Eur 
Arch Oto-Rhino-Laryngology (under review)
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
